Recruiting

Gene therapy injection for moderate knee arthritis

Plain-English translation of NCT07198555 on ClinicalTrials.gov ↗ · Source last updated November 2025 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing , a new gene therapy treatment for moderate knee osteoarthritis. The medication works by delivering a therapeutic gene directly into your knee joint through an injection. Researchers want to understand whether this treatment is safe and whether it helps reduce pain and improve knee function in people who haven't responded well to standard arthritis medications.

Many people with moderate knee osteoarthritis don't get enough relief from conventional medications, and their symptoms come back when they stop taking those drugs. This trial exists to see if a newer approach—using gene therapy—might offer a better solution for people in this situation.

Do you qualify?

You likely qualify if…

you have been diagnosed with moderate knee osteoarthritis (specifically Kellgren-Lawrence grade 2 or 3)
you have tried standard arthritis medications but your pain has returned or gotten worse after stopping them
your knee pain score is at least 8 during the screening period
your body mass index (BMI) is between 18.0 and 35.0
you are willing to use effective contraception and not plan to have children for at least 52 weeks after receiving the treatment
you have low levels of antibodies to this treatment in your blood

You likely don't qualify if…

you have a history of hepatitis B, hepatitis C, HIV, or other serious infections
you are currently pregnant, breastfeeding, or planning to become pregnant in the next 52 weeks
you have a bleeding disorder or are taking blood-thinning medications
you have a history of cancer or genetic therapy or stem cell therapy
you have had a vaccination within 30 days before or after your planned treatment date

What participation looks like

The trial has two phases. In Phase Ia, you would receive either the treatment or a placebo injection into your knee. In Phase Ib, the study becomes double-blind, meaning neither you nor the researchers know who gets the real treatment. You'll have multiple visits for monitoring, blood tests, and imaging scans (like MRI) to track your pain levels and how well your knee is healing. The entire study spans 52 weeks from your injection date.

AI-generated summary from trial data · Jun 21, 2026 · Not medical advice

Trial locations(2 sites)

China

Shenzhen Second People's Hospital, Shenzhen, Guangdong

The Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality

Gene therapy injection for moderate knee arthritis

What is this trial?

Do you qualify?

What participation looks like

Trial locations(2 sites)

Key details

Contact the research team directly

Interested in joining?